MedTrace Logo

Ditefossol Sodium 3% Eye Drops in Patients With Dry Eye

NCT06560580 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2024-08-19

No results posted yet for this study

Summary

This study aimed to evaluate the efficacy of 3% diquafosol sodium eye drops in treating dry eye disease (DED) across different age groups using a propensity score-matched longitudinal design.

Conditions

Interventions

DRUG

3% Diquafosol Sodium Eye Drops

Each patient was prescribed 3% (5 mL: 150 mg) diquafosol sodium eye drops \[Diquas®, provided by Santen Pharmaceutical (China) Co., Ltd.\], recommended to instill one drop six times daily for 3 months. Follow-up examinations were conducted at baseline, 1 month, and 3 months after treatment initiation.

Sponsors & Collaborators

  • Tianjin Eye Hospital

    lead OTHER

Principal Investigators

  • Yi Zhang · Tianjin Eye Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
23 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-15
Primary Completion
2023-07-20
Completion
2024-07-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06560580 on ClinicalTrials.gov